A review on understanding chemobrain and neuroprotection effects on breast cancer therapies on cognitive function

Abstract Breast cancer (BC) patients are frequently facing Cognitive impairment (CI), commonly called as “chemobrain,” succeeding various therapies such as chemo, immuno, targeted, radio, and endocrine therapies. This review analyze and reveals about different mechanisms or process involved in the cancer-related CI, which including hormonal dysregulation, hereditary predisposition, neuroinflammation, blood-brain barrier disruption, and oxidative stress. Analytical and screening problems are studied through neuroimaging advancements, artificial intelligence (AI)-assisted CI assessments, and neuropsychological studies. The amalgamation AI demonstrated novel possibilities for early identification, individual risk assessment, and AI-aided CI therapy. Besides, we bring together recent progress on neuroprotective approaches, such as drug treatments, CI therapy, physical activity, and digital intrusions. This review amalgamates the possible molecular mechanisms, clinical identifications, and AI progressions to provide a thorough agenda for indulgent and offering possible suggestions for CI management in BC patients, highlighting the prominence of assimilating mental health into typical oncology precaution and survivorship monitoring.